Leflunomide plus pomalidomide with dexamethasone for relapsed myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial studies whether a combination of three medicines (leflunomide, pomalidomide, and dexamethasone) can better treat multiple myeloma that has come back or stopped responding. It may help people who are not good candidates for transplant and who have measurable disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your legal representative) can sign consent, and you agree to use stored tumor tissue from a past biopsy (or the study may approve an exception).
- Your performance status is good (ECOG 0 to 2) and you have an expected survival of more than 3 months.
- Your multiple myeloma has measurable disease based on blood or urine lab markers.
- Your cancer has come back or not responded after at least 1 prior treatment plan that included both a proteasome inhibitor and an immune-modulating medicine, and transplant is not recommended.
- Your blood counts and organ function meet safety levels: low white blood cells, platelets, hemoglobin, liver tests, or kidney function may make you ineligible.
- You have no key “stop signs” such as prior leflunomide use, pomalidomide-resistant disease, certain infections (including TB or hepatitis), HIV, or recent other cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study compares two combination treatments for multiple myeloma that has come back or not gone away (relapsed or refractory). It aims to see whether mezigdomide, along with bortezomib and dexamethasone, works better than pomalidomide with those same medicines.
This study tests a new combination of two drugs, teclistamab and pomalidomide, against the usual treatment of three drugs for multiple myeloma that has come back shortly after a standard treatment. The goal is to see if the new combination works better or is safer.
This trial is testing a combination of three drugs (carfilzomib, cyclophosphamide, and dexamethasone) for people with multiple myeloma that has come back or stopped responding to previous treatments, especially if they've already had lenalidomide. The goal is to see if this combination can help control the cancer.
This study tests a new combination of drugs for people with multiple myeloma that has come back or stopped responding to previous treatments. The goal is to see if the combination helps control the disease.
This trial tests a new combination treatment for multiple myeloma and similar blood cancers. It aims to see if the combination works better than current options and may help people whose cancer has not responded to other treatments.
This clinical trial tests a combination of three drugs—mezigdomide, carfilzomib, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to prior treatments, especially when the disease has spread outside the bone (extramedullary disease). It aims to see if this new cocktail can shrink tumors and control myeloma more effectively.
Hear when a new Recurrent Plasma Cell Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.